S&P 500 3,852.36

DOW 32,920.46

QQQ 306.18

MarketBeat Week in Review – 1/30 - 2/3

“Future Fuel” will unleash $11 trillion wave of wealth (Ad)

State of the Union: Biden sees economic glow, GOP sees gloom

Why a new Alzheimer's drug is having a slow US debut

“Future Fuel” will unleash $11 trillion wave of wealth (Ad)

Sri Lanka marks independence anniversary amid economic woes

Tesla hikes price of Model Y after US alters tax credit rule

“Future Fuel” will unleash $11 trillion wave of wealth (Ad)

Disney World unions vote down offer covering 45,000 workers

Route to Super Bowl dangerous for Mexico's avocado haulers

S&P 500 3,852.36

DOW 32,920.46

QQQ 306.18

MarketBeat Week in Review – 1/30 - 2/3

“Future Fuel” will unleash $11 trillion wave of wealth (Ad)

State of the Union: Biden sees economic glow, GOP sees gloom

Why a new Alzheimer's drug is having a slow US debut

“Future Fuel” will unleash $11 trillion wave of wealth (Ad)

Sri Lanka marks independence anniversary amid economic woes

Tesla hikes price of Model Y after US alters tax credit rule

“Future Fuel” will unleash $11 trillion wave of wealth (Ad)

Disney World unions vote down offer covering 45,000 workers

Route to Super Bowl dangerous for Mexico's avocado haulers

S&P 500 3,852.36

DOW 32,920.46

QQQ 306.18

MarketBeat Week in Review – 1/30 - 2/3

“Future Fuel” will unleash $11 trillion wave of wealth (Ad)

State of the Union: Biden sees economic glow, GOP sees gloom

Why a new Alzheimer's drug is having a slow US debut

“Future Fuel” will unleash $11 trillion wave of wealth (Ad)

Sri Lanka marks independence anniversary amid economic woes

Tesla hikes price of Model Y after US alters tax credit rule

“Future Fuel” will unleash $11 trillion wave of wealth (Ad)

Disney World unions vote down offer covering 45,000 workers

Route to Super Bowl dangerous for Mexico's avocado haulers

S&P 500 3,852.36

DOW 32,920.46

QQQ 306.18

MarketBeat Week in Review – 1/30 - 2/3

“Future Fuel” will unleash $11 trillion wave of wealth (Ad)

State of the Union: Biden sees economic glow, GOP sees gloom

Why a new Alzheimer's drug is having a slow US debut

“Future Fuel” will unleash $11 trillion wave of wealth (Ad)

Sri Lanka marks independence anniversary amid economic woes

Tesla hikes price of Model Y after US alters tax credit rule

“Future Fuel” will unleash $11 trillion wave of wealth (Ad)

Disney World unions vote down offer covering 45,000 workers

Route to Super Bowl dangerous for Mexico's avocado haulers

OTCMKTS:GSTC

GlobeStar Therapeutics - GSTC Stock Forecast, Price & News

$0.0087

0.00 (0.00%)

(As of 02/3/2023 12:00 AM ET)

Add

Today's Range: $0.0061
▼
$0.0093
50-Day Range: $0.01
▼
$0.02
52-Week Range: $0.00
▼
$0.02

Volume: 2.75 million shs
Average Volume: 4.27 million shs
Market Capitalization: $6.70 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

About GlobeStar Therapeutics (OTCMKTS:GSTC) Stock

GlobeStar Therapeutics Corp. is a clinical stage biotechnology company, which engages in the manufacture and patented formulation of previously approved drugs for the treatment of Multiple Sclerosis. The company was founded by David P. Summers in 2011 and is headquartered in Richland, WA.

Read More

Receive GSTC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GlobeStar Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

GSTC Stock News Headlines

January 3, 2023 | finance.yahoo.com

GlobeStar Therapeutics Corporation (GSTC)

November 27, 2022 | reuters.com

GlobeStar Therapeutics Corp

February 5, 2023 | Tradewins (Ad)

Know Your Profit Potential BEFORE You Trade!

I’m Chuck Hughes, ten-time trading champion and author of the coveted e-book, “Options Trading Made Easy”, the strategy guide that will teach you to calculate your trade’s profit potential before you risk any capital. Click here for a free copy now!

August 2, 2022 | finance.yahoo.com

GlobeStar Therapeutics Corporation Update on Recent Activity

March 1, 2022 | finance.yahoo.com

GlobeStar Therapeutics Corporation Awards New York Bay Capital, LLC Investment Banking Contract

March 1, 2022 | finance.yahoo.com

CORRECTING and REPLACING GlobeStar Therapeutics Corporation Awards New York Bay Capital, LLC Investment Banking Contract

February 4, 2022 | finance.yahoo.com

GlobeStar Therapeutics Corporation Addresses the Potential Link Between Neurodegenerative Disease and Parkinson’s Disease

January 12, 2022 | nasdaq.com

GlobeStar Therapeutics Corp (GSTC)

February 5, 2023 | Wall Street Watch Dogs (Ad)

“Future Fuel” will unleash $11 trillion wave of wealth

The next major energy revolution is unfolding right now. And it could hand early investors as much as 46,700% gains…

October 18, 2021 | finance.yahoo.com

GlobeStar Therapeutics Corporation To Be Seen In The Washington Football Team Yearbook All Season

October 18, 2021 | finance.yahoo.com

GlobeStar Therapeutics Corporation Unveils New Corporate Website and Branding Campaign

October 18, 2021 | finance.yahoo.com

GlobeStar Therapeutics Corporation Files New 8K Statement Focused On Progress, Market Acceptance, And A Potential Game-Changing Drug For Multiple Sclerosis

October 18, 2021 | finance.yahoo.com

GlobeStar Therapeutics Corporation Additional Progress Toward A U.S.-Based Clinical Trial.

October 18, 2021 | finance.yahoo.com

GlobeStar Therapeutics Corporation Has Been Upgraded to the QB Tier on OTC Markets

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive GSTC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GlobeStar Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

GSTC Company Calendar

Today: 2/05/2023
Fiscal Year End: 9/30/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: OTCMKTS:GSTC
CUSIP: N/A
CIK: 1502152
Web: angiosoma.com
Phone: (206) 451-1970
Fax: N/A
Employees: 1
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-1,490,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: -16,688.16%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.01
Quick Ratio: 0.01

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: 770,360,000
Free Float: N/A
Market Cap: $6.70 million
Optionable: Not Optionable
Beta: 1.09

Key Executives

James C. Katzaroff
Chairman, President, CEO & Secretary

Robert Chicoski
Chief Financial Officer & Treasurer

David Croom
Executive Vice President

Brooke Greenwald
Chief Marketing Officer

Key Competitors

View All Competitors

GSTC Stock - Frequently Asked Questions

How have GSTC shares performed in 2023?: GlobeStar Therapeutics' stock was trading at $0.0133 at the start of the year. Since then, GSTC stock has decreased by 34.6% and is now trading at $0.0087.
View the best growth stocks for 2023 here.
Are investors shorting GlobeStar Therapeutics?: GlobeStar Therapeutics saw a increase in short interest in December. As of December 30th, there was short interest totaling 168,600 shares, an increase of 143.6% from the December 15th total of 69,200 shares. Based on an average trading volume of 18,869,100 shares, the days-to-cover ratio is presently 0.0 days.
View GlobeStar Therapeutics' Short Interest.

What is GlobeStar Therapeutics' stock symbol?: GlobeStar Therapeutics trades on the OTCMKTS under the ticker symbol "GSTC."
How do I buy shares of GlobeStar Therapeutics?: Shares of GSTC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is GlobeStar Therapeutics' stock price today?: One share of GSTC stock can currently be purchased for approximately $0.01.
How much money does GlobeStar Therapeutics make?: GlobeStar Therapeutics (OTCMKTS:GSTC) has a market capitalization of $6.70 million.
How can I contact GlobeStar Therapeutics?: GlobeStar Therapeutics' mailing address is 2500 WILCREST DRIVE 3RD FLOOR, HOUSTON TX, 77042. The official website for the company is angiosoma.com. The company can be reached via phone at (206) 451-1970 or via email at investors@angiosoma.info.

This page (OTCMKTS:GSTC) was last updated on 2/5/2023 by MarketBeat.com Staff

Web Analytics

Get 30 Days of MarketBeat All Access Free

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial